Influence of serum protein binding on the uptake and retention of idarubicin by sensitive and multidrug resistant human leukemic cells

European Journal of Clinical Pharmacology

Volumn 55, Issue 5, 1999, Pages 369-373

  Kessel, M ^a   Gieseler, F ^b   Woodcock, B G ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Idarubicin; Multidrug resistance; Protein binding

Indexed keywords

GLYCOPROTEIN P; IDARUBICIN; VERAPAMIL;

ARTICLE; CYTOSTASIS; DRUG EFFICACY; DRUG RETENTION; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL;

ANTI-ARRHYTHMIA AGENTS; BLOOD PROTEINS; CELL LINE; DRUG RESISTANCE, MULTIPLE; HUMANS; HYPERSENSITIVITY; IDARUBICIN; LEUKEMIA; PROTEIN BINDING; TIME FACTORS; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0032817587     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050642     Document Type: Article

References (22)

1. Goebel M (1993) Oral idarubicin - An anthracycline derivative with unique properties. Ann Hematol 66: 33-43
2. Van der Heyden S, Gheuens E, DeBruijn E, Van-Oosterom A, Maes R (1995) P-gp: Clinical significance and methods of analysis. Crit Rev Clin Lab Sci 32: 221-264
3. Rahman A, Husain SR, Verma M, Siddiqui J, Agresti M, Center M, Safa AR, Glazer RI (1992) Liposome-mediated modulation of multidrug resistance in human HL60 leukemia cells. J Natl Cancer Inst 84: 1909-1915
4. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA (1993) Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil and cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 82: 1288-1299
5. Ford JM, Hait WN (1993) Pharmacologic circumvention of multidrug resistance. Cytotechnology 12: 171-212
6. Häussermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M (1991) Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 40: 53-59
7. Kuffel MJ, Reid JM, Ames MM (1992) Anthracyclines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30: 51-57
8. Tidefelt U, Sundmann-Engberg B, Paul C (1991) Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells. Cancer Chemother Pharmacol 29: 7-12
9. Gieseler F, Biersack H, Brieden T, Manderscheid J, Nussler V (1994) Cytotoxicity of anthracyclines: Correlation with cellular uptake, intracellular distribution and DNA binding. Ann Hematol 69: 13-17
10. Ackermann H (1998) Biometrische Analyse von Stichproben. 6th Edn., Epsilon-Verlag, Darmstadt
11. Adria Laboratories (1990) Idamycin Package Insert. Columbus, OH
12. Eksborg S, Söderberg M, Nilsson B, Antila K (1990) Plasma pharmacokinetics of idarubicin and its 13-hydroxy metabolite after intravenous and oral administration under fasting and non-fasting conditions. Acta Oncol 29: 921-925
13. Hargrave RM, Davey MW, Davey RA, Kidman AD (1995) Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anticancer Drugs 6: 432-437
14. Muindi J, Youn C (1990) In vitro interactions of anthracyclines with human low-density lipoproteins. Proc Am Assoc Clin Res (Washington DC) 31: Abstract 1049
15. Gross AS, Heuer B, Eichelbaum M (1988) Stereoselective protein binding of verapamil enantiomers. Biochem Pharmacol 37: 4623-4627
16. Bates SE, Regis JI, Robey RW, Zhan Z, Scala S, Meadows BJ (1994) Chemoresistance in the clinic: Overview 1994. Bull Cancer 9: 55-61
17. Padrini R, Barbieri E, Piovan D, Toffoli M, Motta A, Trevi GP, Ferrari M (1985) Plasma levels and myocardial content of verapamil, norverapamil and two N-alkyl metabolites in man. Eur J Clin Pharmacol 28: 653-657
18. Scheithauer W, Kornek G, Kastner J, Raderer M, Locker G, Depisch D, Pidlich J, Tetzner C (1993) Phase II study of D-verapamil and doxorubicin in patients with metastatic colorectal cancer. Eur J Cancer 29: 2337-2338
19. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE (1995) Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 13: 1985-1994
20. Stratmann G, Hölzer D, Hoffmann WK, Ottmann OG, Woodcock BG (1998) Modulation of vincristine cytotoxicity by dexverapamil in sensitive and resistant HL-60 cell lines as a function of extracellular protein binding. Int J Clin Pharmacol Ther 36: 103-106
21. Lehnert M, Emerson S, Dalton WS, Salmon SE (1993) Reversal of mdr1: How to evaluate clinical usefulness of chemosensitizers in vitro. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP (eds) Drug Resistance in Leukemia and Lymphoma. The Clinical Value of Laboratory Studies. Harwood Academic Publishers, Chur, Switzerland; pp 183-188
22. Smith CD, Zilfou JT, Zhang X, Hudes GR, Tew KD (1995) Modulation of P-gp activity by estramustine is limited by binding to plasma proteins. Cancer 75: 2597-2604